Rapamycin in combination with other compound or inhibitors had enhanced efficacy against prostate cancer [37] or led to decreased cell proliferation [38], and Giovanni Luca Gravina work also suggested that PI3K/Akt/mTOR inhibitors can be used in hormone-insensitive prostate cancer models [39]. This evidence concerns the gene AKT1 and prostate carcinoma.